Naringenin group ( ) Control group ( ) valuesAge, years 23.6 ± 12.7 24.3 ± 12.1 0.21 Gender, male/female 27/20 29/19 0.77 Smoking, n (%) 19 (40.4) 21 (43.8) 0.74 Alcoholic intake, n (%) 17 (36.2) 18 (37.5) 0.89 Body mass index, kg/m2 25.6 ± 6.9 24.9 ± 7.2 0.14 Osteosarcoma types Intramedullary osteosarcoma 39 (83.0) 38 (79.2) 0.64 Juxtacortical osteosarcoma 7 (14.9) 8 (16.7) 0.81 Extraskeletal osteosarcoma 1 (21.3) 1 (41.7) 1.00 Osteosarcoma grades G1, n (%) 8 (17) 7 (14.6) 0.75 G2, n (%) 9 (19.1) 10 (20.8) 0.84 G3, n (%) 22 (46.8) 24 (50) 0.76 G4, n (%) 8 (17) 7 (14.6) 0.75 Osteosarcoma volume Before surgery 248.7 ± 124.3 c.c. 260.5 ± 113.7 c.c. 0.13 After surgery 3.9 ± 3.9 c.c. 3.5 ± 3.5 c.c. 0.24 Chemotherapy, n (%) 35 (74.5) 33 (68.8) 0.77 Resection length, cm 13.4 ± 5.9 12.7 ± 6.2 0.25 Stem diameter, cm 11.7 ± 3.6 10.5 ± 4.3 0.16 Site Cancer treatment types Osteosarcoma surgery 47 (100) 48 (100) 1.00 Chemotherapy 47 (100) 48 (100) 1.00 Radiotherapy 5 (10.6) 6 (12.5) 0.78 Rehabilitation and supportive care 47 (100) 48 (100) 1.00 Femur, n (%) 31 (66) 30 (62.5) 0.73 Tibia, n (%) 12 (25.5) 11 (22.9) 0.77 Others, n (%) 4 (8.5) 7 (14.6) 0.36 Histologic type Osteoblastic, n (%) 20 (42.6) 18 (37.5) 0.62 Chondroblastic, n (%) 14 (29.8) 17 (35.4) 0.56 Fibroblastic, n (%) 9 (19.1) 8 (16.7) 0.75 Others, n (%) 4 (8.5) 5 (10.4) 0.97 Differentiation status High, n (%) 31 (66) 33 (68.8) 0.71 Low, n (%) 16 (34) 15 (31.3) 0.77 Pulmonary metastasis, n (%) 4 (8.5) 5 (10.4) 0.97